Search Result

Results for "

26b pde Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Phosphodiesterase (PDE) (654) 5-HT Receptor (2) Adenosine Deaminase (3) Adenosine Receptor (15) Adenylate Cyclase (2) Adrenergic Receptor (4) Akt (3) Amyloid-β (4) Androgen Receptor (1) AP-1 (1) Apoptosis (63) ATTECs (1) Aurora Kinase (1) Autophagy (30) Bacterial (14) Bcl-2 Family (2) BCRP (1) Beta-secretase (1) Biochemical Assay Reagents (3) Calcium Channel (7) Calmodulin (2) Carbonic Anhydrase (1) Casein Kinase (2) Caspase (2) CDK (2) Cholinesterase (ChE) (3) Collagen (1) COX (3) CXCR (1) Cytochrome P450 (3) DNA/RNA Synthesis (1) Dopamine Receptor (2) Drug Derivative (6) Drug Intermediate (5) Drug Isomer (1) Drug Metabolite (8) E1/E2/E3 Enzyme (1) EGFR (3) Endogenous Metabolite (33) Environmental Pollutants (1) Epigenetic Reader Domain (3) ERK (2) Fungal (2) GABA Receptor (4) GLP Receptor (1) Glucocorticoid Receptor (4) GPR35 (1) GSK-3 (2) Guanylate Cyclase (2) HDAC (12) Heme Oxygenase (HO) (1) Histamine Receptor (5) HIV (8) HSP (1) IFNAR (2) iGluR (1) IKK (3) IKZF Family (1) Influenza Virus (4) Interleukin Related (28) Isotope-Labeled Compounds (39) JAK (2) JNK (1) Keap1-Nrf2 (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (2) mAChR (5) MAPKAPK2 (MK2) (1) Microphthalmia Associated Transcription Factor (MITF) (1) MicroRNA (12) Mitochondrial Metabolism (4) MMP (1) Molecular Glues (7) Monoamine Oxidase (1) mTOR (4) Myosin (1) Na+/H+ Exchanger (NHE) (1) NAMPT (1) NF-κB (8) NO Synthase (15) NOD-like Receptor (NLR) (2) Nuclear Factor of activated T Cells (NFAT) (2) Orphan GPCR (1) P2Y Receptor (1) p38 MAPK (5) Parasite (2) PARP (1) PGC-1α (1) Phosphatase (1) PI3K (1) PKA (10) PKG (2) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (5) PPAR (3) Prostaglandin Receptor (2) PROTACs (1) RAR/RXR (2) Ras (7) Reactive Oxygen Species (ROS) (5) Reference Standards (83) RSV (5) Sirtuin (1) Small Interfering RNA (siRNA) (69) Sodium Channel (3) Tau Protein (2) TGF-beta/Smad (3) TNF Receptor (32) Toll-like Receptor (TLR) (1) TRP Channel (4) Tyrosinase (1) Wnt (5) β-catenin (4)
By Research Areas:	Cancer (177) Cardiovascular Disease (164) Endocrinology (43) Infection (33) Inflammation/Immunology (255) Metabolic Disease (49) Neurological Disease (185)
Oligonucleotides:	miRNA mimics (3) miRNA antagomirs (3) miRNA agomirs (3) MicroRNAs (12) Rat Pre-designed siRNA Sets (20) Mouse Pre-designed siRNA Sets (20) miRNA inhibitors (3) Human Pre-designed siRNA Sets (29) siRNAs (69)

783

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Targets Recommended: Phosphodiesterase (PDE) Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D1056A3

Lipopolysaccharides, from E. coli O26:B6 LPS, from Escherichia coli (O26:B6)	Toll-like Receptor (TLR)	Inflammation/Immunology
Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A, and can be recognized by the core-specific monoclonal antibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be used to construct various models, such as cellular inflammation models, sepsis, acute lung injury models, adrenal dysfunction models, and bladder infection models, etc . It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

HY-115687

PDE4B-IN-2	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4B-IN-2 is an orally active and selective *PDE4B* inhibitor with an IC₅₀ of 15 nM. PDE4B-IN-2 inhibits PDE4D (IC₅₀=1.7 μM). PDE4B-IN-2 exhibits potent anti-inflammatory effects .

HY-163285

PDE3B-IN-1	Phosphodiesterase (PDE)	Metabolic Disease
PDE3B-IN-1 is a potent selective *PDE3B* inhibitor that demonstrates PDE3B inhibitory activity (pIC₅₀ = 6.5) and >300-fold *PDE3B/A* selectivity .

HY-100326

PDE7-IN-3	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology
Pde7-in-3 (example 2) is an inhibitor of the phosphodiesterase *PDE7* with potential analgesic activity. PDE7-IN-3 can be used to study inflammatory, neuropathic, visceral and nociceptive pain .

HY-117318

PDE12-IN-1	Phosphodiesterase (PDE)	Infection
PDE12-IN-1 is a potent and selective *PDE12* inhibitor with a pIC₅₀ value for enzyme inhibition of 9.1. PDE12-IN-1 increases 2′,5′-linked adenylate polymers (2-5A) levels, and the pEC₅₀ value is 7.7. PDE12-IN-1 shows antiviral activity .

HY-W011336

PDE5-IN-7	Phosphodiesterase (PDE)	Others
PDE5-IN-7 (compound 8) is a selective phosphodiesterase 5 (PDE 5) inhibitor with an IC₅₀ value of 5 nM, while an IC₅₀ of 300 nM for PDE 1 .

HY-124768

PDE12-IN-3	Phosphodiesterase (PDE)	Infection Inflammation/Immunology
PDE12-IN-3 is a phosphodiesterase 12 (PDE12) inhibitor with a pXC₅₀ of 7.68. Antiviral activity .

HY-R00497

*hsa-miR-26b-5p mimic*	MicroRNA	Cancer
hsa-miR-26b-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-26b-5p mimic hsa-miR-26b-5p mimic

HY-RI00497

*hsa-miR-26b-5p inhibitor*	MicroRNA	Cancer
hsa-miR-26b-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-26b-5p inhibitor hsa-miR-26b-5p inhibitor

HY-170788

PDE7A-IN-1	Phosphodiesterase (PDE)	Metabolic Disease
PDE7A-IN-1 is an orally active and selective PDE7A inhibitor with an IC₅₀ of 0.0037 μM against PDE7A. PDE7A-IN-1 shows excellent isozyme selectivity over *PDE7B. PDE7A-IN-1 elevates intracellular cAMP* levels, suppresses ECR5 enhancer activity and reduces sclerostin expression. PDE7A-IN-1 significantly increases bone mineral density in rats. PDE7A-IN-1 can be used for the study of osteoporosis .

HY-112555

PDE7-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE7-IN-2 (compound 2) is a potent PDE7 (phosphodiesterase 7) inhibitor with IC₅₀ value of 2.1 µM. PDE7-IN-2 has the potential for the research of parkinson’s disease .

HY-101490

PDE1-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE1-IN-2 is a *PDE1* inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC₅₀ values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders .

HY-169981

PDE4-IN-24	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-24 (compoud 14h) is a potent inhibitor of *PDE4D* with the IC₅₀ of 0.57 nM and >4100-fold selectivity over other PDE families. PDE4-IN-24 plays an important role in inflammatory disease .

HY-169402A

PDE1-IN-9 hydrochloride	Phosphodiesterase (PDE) NO Synthase Reactive Oxygen Species (ROS) Interleukin Related	Inflammation/Immunology
PDE1-IN-9 (Compound 7a) hydrochloride is a selective inhibitor for phosphodiesterase 1 (PDE1), that inhibits *PDE1C* with an IC₅₀ of 11 nM. PDE1-IN-9 hydrochloride reduces mRNA expression of IL-1β, IL-6, TNF-α and iNOS, inhibits the production of nitric oxide (NO) and reactive oxygen species (ROS). PDE1-IN-9 hydrochloride exhibits good metabolic stability in rat liver microsomes .

HY-114727

PDE7-IN-4	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE7-IN-4 is a phosphodiesterase 7 (PDE7) inhibitor with activity that increases intracellular cyclic adenosine monophosphate (cAMP) levels. PDE7-IN-4 shows potential inhibitory effects in neurotransmission and anti-inflammatory applications. PDE7-IN-4 exerts its biological activity by acting on the cAMP/cAMP response element binding protein (CREB) pathway. The development of PDE7-IN-4 aims to improve its pharmacokinetic characteristics to more effectively target neurodegenerative diseases and other inflammation-related diseases .

HY-174383

PDE3/4-IN-2	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE3/4-IN-2 is a dual *PDE3A* and *PDE4B1* inhibitor, with an IC₅₀ of 0.13 nM against *PDE3A* and 50 nM against *PDE4B1. PDE3/4-IN-2 exhibits higher systemic exposure and longer retention time in lung tissues in ICR mice. PDE*3/4-IN-2 can be used in research on respiratory diseases such as asthma and chronic obstructive pulmonary disease, as well as autoimmune inflammation-related studies .

HY-RI00497A

*hsa-miR-26b-5p antagomir*	MicroRNA	Cancer
hsa-miR-26b-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-26b-5p antagomir hsa-miR-26b-5p antagomir

HY-151174

PDE4-IN-12	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC₅₀s of 3.5 and 15 nM for *PDE4* and *PDE7, respectively (SI=2.71 and 4.27, respectively). PDE*4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs) .

HY-12813

PDE10-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE10-IN-1 is a potent PDE10-IN-1 inhibitor extracted from Patent WO 2013192273 A1, for treating CNS and metabolic disorders.

HY-173477

JR5-26B	Apoptosis	Cancer
JR5-26B is an orally active apoptosis inducer. JR5-26B induces cell death through copper-mediated apoptosis and necroptosis. JR5-26B exhibits antiproliferative activity on MIA PaCa-2, PANC-1, PAN02, SU.86.86, and KPC-2 cells with IC₅₀s of 0.6, 4.4, 8.0, 1.1, and 3.4μM, respectively .

HY-E71311

*β-Mannanase 26B, Clostridium cellulovorans*	Biochemical Assay Reagents	Others
β-Mannanase 26B, Clostridium cellulovorans (EC 3.2.1.78) is an enzyme with system name 4-beta-D-mannan mannanohydrolase. This enzyme catalyses the following chemical reaction: Random hydrolysis of (1->4)-beta-D-mannosidic linkages in mannans, galactomannans and glucomannans.

HY-R00496

*hsa-miR-26b-3p mimic*	MicroRNA	Cancer
hsa-miR-26b-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-26b-3p mimic hsa-miR-26b-3p mimic

HY-179337

PDE2-IN-1	Phosphodiesterase (PDE) PKA	Neurological Disease
PDE2-IN-1 is a potent and orally active *PDE2* inhibitor with an IC₅₀ of 0.6 μM, demonstrating neuroprotective effects. PDE2-IN-1 modulates the PKA/CREB/BDNF signaling pathway by inhibiting PDE2. PDE2-IN-1 improves memory deficits and cognitive impairment in an okadai acid (OKA)-induced Alzheimer’s disease (AD) mouse model. PDE2-IN-1 can be used for the research of AD .

HY-131710

PDE5-IN-3	Phosphodiesterase (PDE) EGFR Wnt Apoptosis	Cancer
PDE5-IN-3 (compound 11j) is a potent *PDE5* inhibitor with an IC₅₀ of 1.57 nM. PDE5-IN-3 shows moderate EGFR inhibition with IC₅₀ of 5.827 µM. PDE5-IN-3 significantly inhibits the Wnt/β-catenin pathway (IC₅₀=1286.96 ng/mL). PDE5-IN-3 induces the intrinsic apoptotic mitochondrial pathway in HepG2 cells. PDE5-IN-3 has strong antitumor activity .

HY-112704

PDE5-IN-2	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-2 is a potent, highly selective, and orally active *PDE5* inhibitor, with an IC₅₀ of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC₅₀s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity .

HY-50865

PDE-9 inhibitor	Phosphodiesterase (PDE)	Neurological Disease
PDE-9 inhibitor is useful for neurodegenerative diseases.

HY-156434

PDE11A4-IN-1	Phosphodiesterase (PDE)	Neurological Disease
PDE11A4-IN-1 (compound 23b) is a potent and selective *PDE11A4* inhibitor with an IC₅₀ of 12 nM. PDE11A4-IN-1 show high selectivity for PDE11A4 over PDE1, PDE2, PDE7, PDE8, and PDE9 .

HY-176524S

PDE3/4-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE3/4-IN-3 (Compound 7) is an orally active dual *PDE3/4* inhibitor with IC₅₀s of 0.17 and ≤50 nM for PDE3A and PDE4B2, respectively. PDE3/4-IN-3 significantly inhibits methacholine-induced bronchoconstriction in guinea pigs. PDE3/4-IN-3 can be used for chronic obstructive pulmonary disease (COPD) and asthma research .

HY-179504

PDE4B-IN-6	Phosphodiesterase (PDE) TNF Receptor	Inflammation/Immunology
PDE4B-IN-6 (compound 4i) is a potent and selective *PDE4B* inhibitor with an IC₅₀ of 7.42 nM. PDE4B-IN-6 shows ~195- and ~169-fold selectivity for PDE4B over *PDE4A* (IC₅₀ = 1540 nM) and *PDE4C* (IC₅₀ = 1260 nM), respectively. PDE4B-IN-6 increases cAMP level and suppresses TNF-α expression. PDE4B-IN-6 shows favorable antioxidant profiles and low cytotoxicity. PDE4B-IN-6 can be used for chronic obstructive pulmonary disease (COPD) research .

HY-176234

PDE4-IN-28	Phosphodiesterase (PDE) TNF Receptor NO Synthase Bacterial	Infection Neurological Disease Inflammation/Immunology
PDE4-IN-28 (Compound G1) is a *PDE4D* inhibitor (IC₅₀: 29 nM). PDE4-IN-28 inhibits the production of TNF-α and NO (IC₅₀: 13.32 and 2.32 μM, respectively). PDE4-IN-28 exhibits anti-inflammatory, antibacterial and analgesic effects in a rat pressure ulcer (PU) model and promotes HUVEC cell migration, thereby accelerating wound healing .

HY-RI02857A

*mmu-miR-26b-3p antagomir*	MicroRNA	Cancer
mmu-miR-26b-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-26b-3p antagomir mmu-miR-26b-3p antagomir

HY-170956

BTN3A1 ligand-1	Drug Intermediate	Inflammation/Immunology
BTN3A1 ligand-1 (Compound 26b) is a triazole-containing aryl/acyloxyalkyl phosphonate prodrug. BTN3A1 ligand-1 can stimulate T cell proliferation (EC₅₀ : 0.49 nM) and interferon γ secretion. BTN3A1 ligand-1 has certain plasma stability and can be used in related immunotherapy research .

HY-W171611

PDE-IN-3	Phosphodiesterase (PDE)	Neurological Disease
PDE-IN-3 (compound 23) is a phosphodiesterase (PDE) inhibitor with an IC₅₀ of 260 μM .

HY-149661

PDE5-IN-11	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-11 is a potent inhibitor of *PDE5* with an IC₅₀ of 40 nM. PDE5-IN-11 also inhibits *PDE4* and *PDE6* with IC₅₀s of 1.78 and 0.09 μM, respectively .

HY-R02857

*mmu-miR-26b-3p mimic*	MicroRNA	Cancer
mmu-miR-26b-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-26b-3p mimic mmu-miR-26b-3p mimic

HY-162583

PDE4-IN-17	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-17 (compound 4e) is a potent *PDE4* inhibitor. PDE4-IN-17 inhibits *PDE4B* and *PDE4D* with IC₅₀s of 10.0 and 15.2 nM, respectively. PDE4-IN-17 has good oral bioavailability (F=66%) and longer half-life (t_1/2=2.0 h) in SD rats .

HY-RI02857

*mmu-miR-26b-3p inhibitor*	MicroRNA	Cancer
mmu-miR-26b-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-26b-3p inhibitor mmu-miR-26b-3p inhibitor

HY-RI00496

*hsa-miR-26b-3p inhibitor*	MicroRNA	Cancer
hsa-miR-26b-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-26b-3p inhibitor hsa-miR-26b-3p inhibitor

HY-R00497A

*hsa-miR-26b-5p agomir*	MicroRNA	Cancer
hsa-miR-26b-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-26b-5p agomir hsa-miR-26b-5p agomir

HY-R02857A

*mmu-miR-26b-3p agomir*	MicroRNA	Cancer
mmu-miR-26b-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-26b-3p agomir mmu-miR-26b-3p agomir

HY-R00496A

*hsa-miR-26b-3p agomir*	MicroRNA	Cancer
hsa-miR-26b-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-26b-3p agomir hsa-miR-26b-3p agomir

HY-RS07280

KIF26B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
KIF26B Human Pre-designed siRNA Set A contains three designed siRNAs for KIF26B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

KIF26B Human Pre-designed siRNA Set A KIF26B Human Pre-designed siRNA Set A

HY-RS15680

VPS26B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
VPS26B Human Pre-designed siRNA Set A contains three designed siRNAs for VPS26B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VPS26B Human Pre-designed siRNA Set A VPS26B Human Pre-designed siRNA Set A

HY-RS03448

CYP26B1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP26B1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP26B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP26B1 Human Pre-designed siRNA Set A CYP26B1 Human Pre-designed siRNA Set A

HY-170435

PDE5-IN-13	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC₅₀ of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active .

HY-128060

PDE5-IN-42	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-42 (Compound 42) is a potent and orally active *PDE5* inhibitor with an IC₅₀ of 0.04 nM. PDE5-IN-42 maintains selectivity over PDE6 and PDE11 .

HY-W787896

PDE4-IN-25	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-25 (compound 12) is a potent inhibitor of *PDE4*，with the IC₅₀ of 0.1 μM. PDE4-IN-25 plays an important role in inflammatory diseases research .

HY-130262

PDE1-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE1-IN-3, compound 4 (WO2019156861), is a selective human phosphodiesterase 1 (PDE1) inhibitor. PDE1-IN-3 inhibits PDE4D and PDE6AB with IC₅₀ values of 23.99 μM and 10 μM, respectively .

HY-161290

PDE5-IN-12	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-12 (compound 4h) is a potent phosphodiesterase-5 (PDE-5) inhibitor with an IC₅₀ of 22 nM. PDE5-IN-12 shows anti-proliferative effects against the aortic cell line .

HY-153766

PDE5-IN-9	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-9 (Compound 59) is a *PDE5* inhibitor (IC₅₀: 11.2 μM). PDE5-IN-9 shows interaction with Gln 817, Tyr 612, and Ala 767 amino acid residues. PDE5-IN-9 can be used for research of cardiovascular disease .

Cat. No.	Product Name

HY-L012

Metabolism/Protease Compound Library

7,056 compounds

Metabolism is the set of life-sustaining chemical reactions in organisms. Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. Acting as catalysts, enzymes are crucial to metabolism - they allow a reaction to proceed more rapidly - and they also allow the regulation of the rate of a metabolic reaction. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. Imbalances in metabolic activities have been found to be critical in a number of pathologies, such as cardiovascular diseases, inflammation, cancer, and neurodegenerative diseases.

MCE designs a unique collection of 7,056 Metabolism/Protease-related small molecules that act as a useful tool for drug discovery of metabolism-related diseases.

HY-L007

Immunology/Inflammation Compound Library

7,846 compounds

The immune system is a host defense system comprising many biological structures and processes within an organism that protects against disease. To function properly, an immune system must detect a wide variety of agents, known as pathogens, from viruses to parasitic worms, and distinguish them from the organism's own healthy tissue. Inflammation is also the body's attempt at self-protection to remove harmful stimuli and begin the healing process. It’s part of the body's immune response. The immune system recognizes damaged cells, irritants, and pathogens, and inflammation begins the healing process. Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation.

MCE designs a unique collection of 7,846 compounds that are useful tool for Immunology/Inflammation research or autoimmune inflammatory diseases drug discovery.

Cat. No.	Product Name	Type

HY-12318G

IBMX 3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine	Fluorescent Dyes
IBMX (3-Isobutyl-1-methylxanthine) (GMP) is IBMX (HY-12318) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor .

HY-16900G

Rolipram

Fluorescent Dyes

Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Cat. No.	Product Name	Type

HY-D1056A3

Lipopolysaccharides, from E. coli O26:B6

LPS, from Escherichia coli (O26:B6)

Biochemical Assay Reagents

Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A, and can be recognized by the core-specific monoclonal antibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be used to construct various models, such as cellular inflammation models, sepsis, acute lung injury models, adrenal dysfunction models, and bladder infection models, etc .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

HY-12318G

IBMX 3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine	Biochemical Assay Reagents
IBMX (3-Isobutyl-1-methylxanthine) (GMP) is IBMX (HY-12318) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor .

HY-W007367

2,6-Dichloropurine	Biochemical Assay Reagents
2,6-Dichloropurine is a pharmaceutical intermediate. 2,6-Dichloropurine can be used to synthesize various PDE inhibitors, human A3 adenosine receptor (AR) antagonists, and CDK inhibitors .

HY-W002463

3-Chlorophenyl boronic acid

Biochemical Assay Reagents

3-Chlorophenylboronic acid is employed as a reactant involved in 1,4-conjugate addition reactions with ethenesulfonamides to form arylethanesulfonamides, Suzuki-Miyaura reactions with dibromotrifluoromethylbenzene, cross-coupling reactions with diazoesters3 or potassium cyanate. 3-Chlorophenylboronic acid is involved in the synthesis of biarylketones and phthalides and synthesis of inhibitors including PDE4 inhibitors among others. 3-Chlorophenyl boronic acid can affect cell migration. 3-Chlorophenyl boronic acid can be used to study wound healing .

HY-16900G

Rolipram

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0014

Icariin Maximum Cited Publications 27 Publications Verification Ieariline	Cardiovascular Disease Flavonols Structural Classification Classification of Application Fields Anti-aging Plants Monophenols Flavonoids Phenols Epimedium brevicornu Maxim. Berberidaceae Inflammation/Immunology Disease Research Fields Source Classification Cancer	Phosphodiesterase (PDE) PPAR Autophagy
Icariin is a flavonol glycoside. Icariin inhibits *PDE5* and *PDE4* activities with IC₅₀s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator.

HY-B0809

Theophylline 10+ Cited Publications 1,3-Dimethylxanthine; Theo-24	Structural Classification Classification of Application Fields Camellia sinensis (L.) O. Ktze. Plants Endogenous metabolite Alkaloids Immune System Disorder Other Alkaloids Disease markers Disease Research Fields Source Classification Theaceae Cancer	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-B0442

Vardenafil 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-113556

Sappanone A 5+ Cited Publications	Flavonoids Classification of Application Fields Leguminosae Caesalpinia sappan L. Plants Inflammation/Immunology Disease Research Fields Isoflavones Source Classification	Phosphodiesterase (PDE) NF-κB Keap1-Nrf2 Reactive Oxygen Species (ROS) TNF Receptor Nuclear Factor of activated T Cells (NFAT) Akt ERK p38 MAPK NO Synthase Interleukin Related COX JNK
Sappanone A is an orally active homoisoflavone found in sappan L. Sappanone A is a *PDE4* and NF-κB inhibitor with anti-inflammatory and antioxidant effect. Sappanone A induces HO-1 expression through activation of Nrf2 pathway. Sappanone A also inhibits RANKL-induced osteoclastogenesis. Sappanone A has great potential in the research of inflammation-related and cardiovascular .

HY-13295

Vinpocetine 5+ Cited Publications Ethyl apovincaminate	Cardiovascular Disease Neurological Disease Classification of Application Fields Anti-aging Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Apocynaceae Alkaloids Piperidine Alkaloids Disease Research Fields Source Classification Cancer	Sodium Channel IKK Phosphodiesterase (PDE)
Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na ⁺ channels. The IC₅₀ value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders .

HY-B0715

Pentoxifylline 10+ Cited Publications BL-191; PTX; Oxpentifylline	Classification of Application Fields Disease Research Fields Cancer	Phosphodiesterase (PDE) Autophagy HIV
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-16558

Butein 5+ Cited Publications 2’,3,4,4’-tetrahydroxy Chalcone	Chalcones Flavonoids other families Classification of Application Fields Anti-aging Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein is a cAMP-specific *PDE* inhibitor with an IC₅₀ of 10.4 μM for *PDE4* . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-122942

Moracin M 4 Publications Verification	Classification of Application Fields Phenols Polyphenols Plants Moraceae Endogenous metabolite Inflammation/Immunology Disease Research Fields Morus alba Linn. Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite NF-κB Autophagy
Moracin M is a phenolic component that can be isolated from Mori Cortex, is a potent phosphodiesterase-4 (PDE4) inhibitor with IC₅₀ values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Moracin M has anti-inflammatory activity .

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0140

Aminophylline 10+ Cited Publications	Classification of Application Fields Inflammation/Immunology Disease Research Fields	Phosphodiesterase (PDE) Adenosine Receptor
Aminophylline is a competitive and non-selective phosphodiesterase (PDE) inhibitor. Aminophylline is a competitive adenosine receptor antagonist. Aminophylline has apulmonary vasodilator action as well as a bronchodilator action and has the potential for asthma research .

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-N1860

3-O-Methylquercetin	Flavonoids Classification of Application Fields Flavones Aconitum apetalum (Huth) B. Fedtsch. Plants Rhamnaceae Inflammation/Immunology Disease Research Fields	Phosphodiesterase (PDE) NO Synthase
3-O-Methylquercetin is an inhibitor of cAMP and CGMP-phosphodiesterase (PDE) with IC₅₀ at 13.8 μM and 14.3 μM, respectively. 3-O-Methylquercetin is an inhibitor of β-secretase with an IC₅₀ of 6.5 μM. 3-O-Methylquercetin has a neuroprotective effect against neuronal death caused by oxidative damage. 3-O-Methylquercetin has strong antiviral activity against poliovirus, coxsackie virus and human rhinovirus. 3-O-Methylquercetin has anti-inflammatory and trachea-relaxing effects and can be used in the study of inflammatory diseases and asthma .

HY-N3945

Glaucine O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396	Infection Alkaloids other families Classification of Application Fields Plants Isoquinoline Alkaloids Glaucium flavum Inflammation/Immunology Disease Research Fields Papaveraceae Source Classification	Phosphodiesterase (PDE) Calcium Channel MMP NF-κB
Glaucine (O,O-Dimethylisoboldine) is an alkaloid extracted from Glaucium flavum that possesses various activities, including cough relief, bronchodilation, anti-inflammatory effects, analgesia, antipyretic properties, and anticancer effects. Glaucine acts as a selective and orally active inhibitor of phosphodiesterase 4 (PDE4), with a K_i of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes. Glaucine induces relaxation of human isolated bronchi by antagonizing calcium channels. Additionally, Glaucine inhibits the activation of NF-κB, leading to a reduction in the expression of the MMP-9 gene, thereby suppressing the migration and invasion of breast cancer cells. Therefore, Glaucine holds potential for research in asthma and breast cancer .

HY-N2443

Tribuloside 1 Publications Verification	Tribulus terrester Linn. Flavonols Flavonoids Zygophyllaceae Phenols Polyphenols Plants Source Classification	Phosphodiesterase (PDE) Bacterial PKA Tyrosinase TRP Channel Microphthalmia Associated Transcription Factor (MITF) Interleukin Related
Tribuloside is a flavonoid and *PDE4* inhibitor (IC₅₀: 6 μM). Tribuloside exhibits antibacterial and antioxidant activities, capable of scavenging DPPH free radicals. Tribuloside also promotes melanogenesis. Tribuloside can be used in the research of hypopigmentary diseases, sun protection, and inflammatory diseases such as acute lung injury .

HY-113469

Cyclic GMP 1 Publications Verification	Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite
Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-N1465

Aristolochic acid D Aristolochic acid-IVa	Structural Classification Monophenols other families Classification of Application Fields Ketones, Aldehydes, Acids Phenols Plants Disease Research Fields Source Classification Cancer	Phosphodiesterase (PDE) CDK Interleukin Related
Aristolochic acid D (Aristolochic acid-IVa) is an orally active *PDE2* (IC₅₀: 4.673 μM) and CDK2 (IC₅₀: 25 μM) inhibitor that can be isolated from Aristolochia indica L. Aristolochic acid D exhibits anti-inflammatory activity and is non-carcinogenic and non-nephrotoxic. Aristolochic acid D can be used in the research of inflammation and tumor-related diseases .

HY-A0027

Fenspiride hydrochloride	Classification of Application Fields Disease Research Fields Endocrinology	Histamine Receptor Phosphodiesterase (PDE)
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases .

HY-B0809A

Theophylline monohydrate 5+ Cited Publications 1,3-Dimethylxanthine monohydrate; Theo-24 monohydrate	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor
Theophylline (1,3-Dimethylxanthine) monohydrate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) monohydrate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) monohydrate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) monohydrate induces apoptosis. Theophylline (1,3-Dimethylxanthine) monohydrate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-N2284

Sophoflavescenol	Flavonols Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Sophora flavescens Aiton Plants Disease Research Fields Source Classification Cancer	Cholinesterase (ChE) Beta-secretase Phosphodiesterase (PDE)
Sophoflavescenol is a prenylated flavonol, which shows great inhibitory activity with IC₅₀ of 0.013 μM against Phosphodiesterase 5 (PDE5), and also inhibits RLAR, HRAR, AGE, BACE1, AChE and BChE with IC₅₀s of 0.30 μM, 0.17 μM, 17.89 μg/mL, 10.98 μM, 8.37 μM and 8.21 μM, respectively.

HY-113469A

Cyclic GMP sodium 1 Publications Verification	Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite
Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-N0014R

Icariin (Standard) Maximum Cited Publications 27 Publications Verification Ieariline (Standard)	Cardiovascular Disease Flavonoids Classification of Application Fields Anti-aging Phenols Epimedium brevicornu Maxim. Plants Berberidaceae Inflammation/Immunology Disease Research Fields Source Classification Cancer	Reference Standards Phosphodiesterase (PDE) PPAR Autophagy
Icariin (Standard) is the analytical standard of Icariin. This product is intended for research and analytical applications. Icariin is a flavonol glycoside. Icariin inhibits *PDE5* and *PDE4* activities with IC₅₀s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator.

HY-121162

Mesembrine (+)-Mesembrine	Alkaloids Structural Classification other families Pyrrole Alkaloids Plants Source Classification	5-HT Receptor Phosphodiesterase (PDE)
Mesembrine ((+)-Mesembrine) a main alkaloid that features an aryloctahydroindole skeleton. Mesembrine is a 5-HT transporter inhibitor with a K_i of 1.4 nM. Mesembrine also inhibits phosphodiesterase 4B (PDE4B) with an IC₅₀ of 7.8 μM .

HY-B0809R

Theophylline (Standard) 5+ Cited Publications 1,3-Dimethylxanthine(Standard); Theo-24 (Standard)	Alkaloids Immune System Disorder Classification of Application Fields Disease markers Camellia sinensis (L.) O. Ktze. Plants Endogenous metabolite Disease Research Fields Source Classification Theaceae Cancer	Reference Standards Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (Standard) is the analytical standard of Theophylline. This product is intended for research and analytical applications. Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-N10149

Nauclefine	Alkaloids Nauclea officinalis (Pirre ex Pitard) Merr. Rubiaceae Plants Indole Alkaloids Source Classification	Phosphodiesterase (PDE) Apoptosis
Nauclefine is an indole alkaloid isolated from Nauclea officinalis. Nauclefine acts as a *PDE3A* modulator to induce cancer cell apoptosis through a PDE3A-SLFN12-dependent death pathway .

HY-N3180

Norbraylin	Toddalia asiatica (L.) Lam. Rutaceae Coumarins Phenylpropanoids Plants Source Classification	Phosphodiesterase (PDE)
Norbraylin, a natural prenylated coumarin, is a *PDE4D2* inhibitor with an IC₅₀ value of 7.15 μM .

HY-N8092

Kushenol B	Flavonoids Classification of Application Fields Leguminosae Flavonones Phenols Polyphenols Plants Sophora flavescens Aiton Disease Research Fields Inflammation/Immunology Source Classification	Phosphodiesterase (PDE)
Kushenol B is an isoprenoid flavonoid isolated from S. flavescens, has antimicrobial, anti-inflammatory and antioxidant activities . Kushenol B has inhibitory activity against cAMP phosphodiesterase (PDE), with an IC₅₀ of 31 µM .

HY-N11262

Sudachitin	Structural Classification Flavonoids Flavones Rutaceae Citrus sudachi Hort. ex Shirai. Plants Source Classification	Phosphodiesterase (PDE) Sirtuin PGC-1α p38 MAPK HSP TNF Receptor NO Synthase Apoptosis
Sudachitin is an orally active compound that potently inhibits mouse *PDE1C* and human *PDE4B, with IC₅₀* values of 5.0 μM and 15.0 μM, respectively. Sudachitin upregulates Sirt1 and PGC‑1α expression in skeletal muscle to regulate energy metabolism and promote mitochondrial biogenesis. Sudachitin improves lipid metabolism, glucose tolerance, insulin sensitivity, energy expenditure, and fatty acid β‑oxidation. Sudachitin activates p38MAPK signaling, induces HSP27 phosphorylation and caspase‑dependent apoptosis, and blocks EGF‑driven keratinocyte migration and proliferation. Sudachitin suppresses LPS‑induced TNF‑α, NO, and iNOS expression in macrophages and shows potent anti‑inflammatory activity. Sudachitin can be used for the research of metabolic syndrome, type 2 diabetes, and psoriasis. .

HY-B1514R

Allantoic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Anagrelide (hydrochloride) (Standard) is the analytical standard of Anagrelide (hydrochloride). This product is intended for research and analytical applications. Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-13295R

Vinpocetine (Standard) Ethyl apovincaminate (Standard)	Apocynaceae Alkaloids Piperidine Alkaloids Structural Classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	Reference Standards Sodium Channel IKK Phosphodiesterase (PDE)
Vinpocetine (Standard) is the analytical standard of Vinpocetine. This product is intended for research and analytical applications. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na ⁺ channels. The IC₅₀ value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders .

HY-113469R

Cyclic GMP (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
Cyclic GMP (Standard) is the analytical standard of Cyclic GMP (HY-113469). This product is intended for research and analytical applications. Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-N2958

Braylin	Structural Classification Rutaceae Coumarins Phenylpropanoids Plants Zanthoxylum tingoassuiba A.St.-Hil. Source Classification	Phosphodiesterase (PDE)
Braylin, a coumarin, is a potent phosphodiesterase-4 (PDE4) inhibitor and is involved in anti-inflammatory and immunomodulation, which may serve as a potential target for the study of immunoinflammatory diseases .

HY-121381

Kuraridine	Chalcones Flavonoids Classification of Application Fields Leguminosae Other Diseases Phenols Polyphenols Sophora flavescens Aiton Plants Disease Research Fields Source Classification	Phosphodiesterase (PDE)
Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC₅₀=0.64 μM) .

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-16558R

Butein (Standard) 2’,3,4,4’-tetrahydroxy Chalcone (Standard)	Structural Classification Chalcones Flavonoids other families Phenols Polyphenols Plants Source Classification	Reference Standards EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-126754

Archangelicin	Coumarins Phenylpropanoids Artemisia kotuchovii Kupr. Umbelliferae Plants Source Classification	Nuclear Factor of activated T Cells (NFAT) Phosphodiesterase (PDE)
Archangelicin is an inhibitor for cAMP-phosphodiesterase (cAMP-PDE) with IC₅₀ >400 μM. Archangelicin inhibits nuclear factor of activated T cell (NFAT) with IC₅₀ of 9 μM. Archangelicin exhibits antitumor and anti-inflammatory .

HY-N6256

Ilexsaponin B2	Cardiovascular Disease Aquifoliaceae Triterpenes Classification of Application Fields Terpenoids Plants Disease Research Fields Tabernaemontana elegans Stapf Source Classification	Phosphodiesterase (PDE)
Ilexsaponin B2 is a saponin isolated from the root of Ilex pubescens Hook. et Arn. Ilexsaponin B2 is a potent phosphodiesterase 5 (PDE5) and PDEI inhibitor with IC₅₀ values of 48.8 μM and 477.5 μM, respectively .

HY-N10156

1,3,5-Trihydroxy-4-prenylxanthone	Flavonoids Leguminosae Plants Other Flavonoids Source Classification Erythrina variegata Linn.	Na+/H+ Exchanger (NHE) Phosphodiesterase (PDE) NO Synthase
1,3,5-Trihydroxy-4-prenylxanthone is a Na ⁺/H ⁺ exchange system inhibitor with a minimum inhibitory concentration of 10 μg/mL . 1,3,5-Trihydroxy-4-prenylxanthone is a phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ value of 3.0 μM . 1,3,5-Trihydroxy-4-prenylxanthone inhibits Lipopolysaccharide (LPS) (HY-D1056)-induced NO production in RAW264.7 macrophages, and has anti-inflammatory activities .

HY-N3945R

Glaucine (Standard) O,O-Dimethylisoboldine (Standard); S-(+)-Glaucine (Standard); NSC 34396 (Standard)	Alkaloids Structural Classification other families Plants Isoquinoline Alkaloids Glaucium flavum Papaveraceae Source Classification	Reference Standards Phosphodiesterase (PDE) Calcium Channel Adrenergic Receptor Dopamine Receptor Influenza Virus
Glaucine (Standard) is the analytical standard of Glaucine. This product is intended for research and analytical applications. Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum with antitussive, bronchodilation and anti-inflammatory properties. Glaucine is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor with Kis of 3.4 μM in human bronchus and polymorphonuclear leukocytes. Glaucine is also a non-selective α-adrenoceptor antagonist, a Ca2+ entry blocker, and a weak dopamine D1 and D2 receptor antagonist. Glaucine has antioxidative and antiviral activities .

HY-N3464

Isopedicin	Flavonoids Flavonones Plants Annonaceae Source Classification Fissistigma oldhamii (Hemsl.) Merr.	Phosphodiesterase (PDE)
Isopedicin potently and concentration-dependently inhibits superoxide anion (O2 U?) production in formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)-activated cells. Isopedicin increases cAMP formation and PKA activity in FMLP-activated cells by inhibiting phosphodiesterase (PDE) activity .

HY-18252R

Avanafil (Standard) TA1790 (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442C

Vardenafil dihydrochloride	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-122942R

Moracin M (Standard)	Structural Classification Phenols Polyphenols Plants Moraceae Endogenous metabolite Morus alba Linn. Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite NF-κB Autophagy Reference Standards
Moracin M (Standard) is the analytical standard of Moracin M. This product is intended for research and analytical applications. Moracin M is a phenolic component that can be isolated from Mori Cortex, is a potent phosphodiesterase-4 (PDE4) inhibitor with IC50 values of 2.9, 4.5, >40, and >100 μM for PDE4D2, PDE4B2, PDE5A1, and PDE9A2, respectively. Moracin M has anti-inflammatory activity .

HY-B0442CR

Vardenafil dihydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442AR

Vardenafil hydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite Reference Standards
Vardenafil (hydrochloride) (Standard) is the analytical standard of Vardenafil (hydrochloride). This product is intended for research and analytical applications. Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442R

Vardenafil (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-W049735R

N,N,O-Tridesmethylvenlafaxine (Standard)	Monophenols Phenols Endogenous metabolite Source Classification	Drug Metabolite Reference Standards Endogenous Metabolite
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-N11965

4'-Methoxyisoagarotetrol	Natural Products Thymelaeaceae Plants Aquilaria sinensis (Lour.) Spreng. Source Classification	Phosphodiesterase (PDE)
4'-Methoxyisoagarotetrol is chromone derivative and shows moderate PDE 3A inhibitory activity (IC₅₀=54 μM) .

HY-N3324

Mangostanol (+)-Mangostanol	Flavonoids Guttiferae Plants Garcinia hanburyi Hook. f. Other Flavonoids Source Classification	Phosphodiesterase (PDE)
Mangostanol ((+)-Mangostanol) is a polyoxygenated xanthone mangostanol, which can be isolated from the shell of Garcinia mangostana, and has inhibitory effect on cAMP phosphodiesterase (PDE) .

Species:	Human (11) Mouse (1)
Tag:	His (9) Tag Free (2) Myc (1) GST (5)
Source:	Sf9 insect cells (7) E. coli (5)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P74647

	PDE2A Protein, Human (sf9, His) cGMP-dependent 3',5'-cyclic phosphodiesterase; CGS-pde; pde2A	Human	Sf9 insect cells
	PDE2A is a cGMP-activated cyclic nucleotide phosphodiesterase that exhibits dual specificity for the second messengers cAMP and cGMP, key regulators in various physiological processes. PDE2A exhibits higher efficiency by covering cAMP and plays an important role in cell growth and migration. PDE2A Protein, Human (sf9, His) is the recombinant human-derived PDE2A protein, expressed by Sf9 insect cells , with C-His labeled tag.

HY-P701960

	PDE4D Protein, Human pde4D; cAMP-specific 3'; 5'-cyclic phosphodiesterase 4D; Dpde3; pde43	Human	E. coli
	PDE4D (Phosphodiesterase 4D) protein, as a hydrolytic enzyme, degrades the second messenger cAMP, a crucial regulator in various physiological processes. Its enzymatic activity in breaking down cAMP underscores PDE4D's pivotal role in modulating cellular signaling cascades, maintaining the intricate balance of intracellular communication mediated by this critical second messenger. PDE4D Protein, Human is the recombinant human-derived PDE4D protein, expressed by E. coli , with tag free.

HY-P71591

	*cGB-PDE* Protein, Mouse (Myc, His)** pde5a; pde5; cGMP-specific 3',5'-cyclic phosphodiesterase; EC 3.1.4.35; cGMP-binding cGMP-specific phosphodiesterase; CGB-pde	Mouse	E. coli
	cGB-PDE protein regulates signal transduction by specifically hydrolyzing cto 5'-GMP, thereby controlling the intracellular concentration of cyclic nucleotides, particularly nitric-oxide-generated cGMP. cGB-PDE Protein, Mouse (Myc, His) is the recombinant mouse-derived cGB-PDE protein, expressed by E. coli , with N-His, C-Myc labeled tag.

HY-P701961

	PDE4D Protein, Human (His) pde4D; cAMP-specific 3'; 5'-cyclic phosphodiesterase 4D; Dpde3; pde43	Human	E. coli
	PDE4D (Phosphodiesterase 4D) protein, as a hydrolytic enzyme, degrades the second messenger cAMP, a crucial regulator in various physiological processes. Its enzymatic activity in breaking down cAMP underscores PDE4D's pivotal role in modulating cellular signaling cascades, maintaining the intricate balance of intracellular communication mediated by this critical second messenger. PDE4D Protein, Human (His) is the recombinant human-derived PDE4D protein, expressed by E. coli , with N-6*His labeled tag.

HY-P75961

	PDE3A Protein, Human (sf9, His-GST) cGMP-inhibited 3',5'-cyclic phosphodiesterase A; CGI-pde A; pde3A	Human	Sf9 insect cells
	PDE3A protein, a cyclic nucleotide phosphodiesterase, targets cAMP, cGMP, and cUMP, crucial in diverse physiological processes. In an E2/17beta-estradiol-induced pro-apoptotic pathway, E2 stabilizes the PDE3A/SLFN12 complex, leading to SLFN12 dephosphorylation and activating its pro-apoptotic ribonuclease activity. This pathway is implicated in tissues with high E2 concentrations, potentially contributing to processes like placenta remodeling. PDE3A Protein, Human (sf9, His-GST) is the recombinant human-derived PDE3A protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P74648

	PDE1C Protein, Human (sf9, His-GST) Phosphodiesterase; pde1C	Human	Sf9 insect cells
	PDE1C, a member of the phosphodiesterase (PDE) family, is a subtype of PDE activated by Ca²⁺.PDE1 plays an important role in the cardiovascular system.PDE inhibitors can reduce neuroinflammation and oxidative stress, stimulate neuroplasticity, and improve symptoms of mental disorders in preclinical models by activating the CAMP-PGKA-CREB and cGMP-PKG pathways.PDE1C Protein, Human (sf9, His-GST) is the recombinant human-derived PDE1C protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P75960

	PDE1B Protein, Human (sf9, His-GST) Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; Cam-pde 1B; pde1B1; pdeS1B	Human	Sf9 insect cells
	PDE1B protein, a cyclic nucleotide phosphodiesterase, displays dual specificity for cAMP and cGMP, essential second messengers in physiological processes. Preferring cGMP as a substrate, PDE1B fine-tunes cellular responses to cyclic nucleotide signaling. Its dual specificity underscores its regulatory role in diverse physiological pathways. PDE1B Protein, Human (sf9, His-GST) is the recombinant human-derived PDE1B protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P75963

	PDE9A Protein, Human (His) High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A; pde9A	Human	E. coli
	PDE9A is a phosphodiesterase that uniquely hydrolyzes second messengers with unparalleled specificity, particularly in the regulation of natriuretic peptide-dependent signaling in the heart, which is critical for the control of cardiac hypertrophy. Its specificity rules out effects on nitric oxide-dependent signaling in the heart. PDE9A Protein, Human (His) is the recombinant human-derived PDE9A protein, expressed by E. coli , with N-His labeled tag.

HY-P75962

	PDE9A Protein, Human (sf9, His-GST) High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A; pde9A	Human	Sf9 insect cells
	PDE9A is a phosphodiesterase that uniquely hydrolyzes second messengers with unparalleled specificity, particularly in the regulation of natriuretic peptide-dependent signaling in the heart, which is critical for the control of cardiac hypertrophy. Its specificity rules out effects on nitric oxide-dependent signaling in the heart. PDE9A Protein, Human (sf9, His-GST) is the recombinant human-derived PDE9A protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P702973

	PDE6D Protein, Human (sf9, GST) pdeD	Human	Sf9 insect cells
	PDE6D Protein, Human (sf9, GST) is the recombinant human-derived PDE6D, expressed by Sf9 insect cells , with GST labeled tag. ,

HY-P703577

	PDE7A1 Protein, Human High affinity 3',5'-cyclic-AMP phosphodiesterase 7A; HCP1; TM22; cAMP-specific phosphodiesterase 7A; pde7A; Homo sapiens; Human; Hydrolase; 3.1.4.53	Human	E. coli
	PDE7A1 Protein, Human is the recombinant human-derived PDE7A1, expressed by E. coli , with tag Free labeled tag. ,

HY-P704128

	PDE4A Protein, Human (sf9, His) Dpde2; phosphodiesterase 4A,cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Human	Sf9 insect cells
	PDE4A Protein, Human (sf9, His) is the recombinant human-derived PDE4A protein, expressed by Sf9 insect cells, with C-His tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-90009S

Tadalafil-d3
Tadalafil-d₃ is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.

HY-12085S

Apremilast-d5
Apremilast-d₅ is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-B0809S

Theophylline-d6
Theophylline-d₆ is the deuterium labeled Theophylline. Theophylline is a nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor blocker, and histone deacetylase (HDAC) activator.

HY-15025S

Sildenafil-d3
Sildenafil-d₃ is deuterium labeled Sildenafil-d₃. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.

HY-B0715S2

Pentoxifylline-d5

Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-15455S

Roflumilast-d4 1 Publications Verification
Roflumilast-d₄ is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC₅₀s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells .

HY-B0442AS

Vardenafil-d5 hydrochloride

Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0204S1

Pimobendan-d3
Pimobendan-d₃ (UD-CG115-d₃) is deuterium labeled Pimobendan (HY-B0204). Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM .

HY-176524S

PDE3/4-IN-3
PDE3/4-IN-3 (Compound 7) is an orally active dual *PDE3/4* inhibitor with IC₅₀s of 0.17 and ≤50 nM for PDE3A and PDE4B2, respectively. PDE3/4-IN-3 significantly inhibits methacholine-induced bronchoconstriction in guinea pigs. PDE3/4-IN-3 can be used for chronic obstructive pulmonary disease (COPD) and asthma research .

HY-17464S1

Cilostazol-d4
Cilostazol-d₄ is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-119708S

Ensifentrine-d6
Ensifentrine-d₆ (RPL-554-d₆) is deuterium labeled Ensifentrine. Ensifentrine (RPL-554) is an inhaled first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and *PDE4* with IC₅₀s of 0.4 nM and 1479 nM, respectively. Ensifentrine has bronchoprotective and anti-inflammatory activities. Ensifentrine can be used for chronic obstructive pulmonary disease (COPD) research .

HY-15025S1

Sildenafil-d8
Sildenafil-d₈ is the deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM .

HY-117605S

N-Desmethyl Sildenafil-d8
N-Desmethyl Sildenafil-d₈ is the deuterium labeled N-Desmethyl Sildenafil (HY-117605). N-Desmethyl Sildenafil is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor .

HY-B0715S

Pentoxifylline-d6

Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-W767865

Cyclic GMP sodium-13C5

Cyclic GMP sodium- ¹³C₅ is the ¹³C-labeled Cyclic GMP sodium (HY-113469A). Cyclic GMP (cGMP) sodium, an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP sodium occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-18252S3

Avanafil-13C5

Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-15455S2

Roflumilast-d3
Roflumilast-d₃ is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.

HY-15455S1

Roflumilast-d4 N-Oxide
Roflumilast-d₄ N-Oxide is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC₅₀s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells .

HY-B0442S

Vardenafil-d5

Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction .

HY-13927S

Acetildenafil-d8
Acetildenafil-d₈ is the deuterium labeled Acetildenafil. Acetildenafil is a structural analog of Sildenafil (HY-15025). Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor.

HY-10978S

Crisaborole-d4
Crisaborole-d₄ is deuterium labeled Crisaborole. Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 μM.

HY-17464S

Cilostazol-d11
Cilostazol-d₁₁ is the deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-A0027AS

Fenspiride-d5

Fenspiride-d₅ is the deuterium labeled Fenspiride. Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases .

HY-17464S2

Cilostazol-d2
Cilostazol-d₂ (OPC 13013-d₂) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of *phosphodiesterase (PDE) 3A, the isoform of PDE* 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-12085S1

Apremilast-d8
Apremilast-d₈ (CC-10004-d₈) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-12085S3

Apremilast-d3
Apremilast-d₃ (CC-10004-d₃) is deuterium labeled Apremilast. Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM .

HY-14252S

Milrinone-d3
Milrinone-d₃ is deuterium labeled Milrinone. Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.

HY-15025AS

Sildenafil citrate-d8
Sildenafil (citrate)-d₈ is the deuterium labeled Sildenafil citrate . Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC₅₀ of 5.22 nM.

HY-15025S3

Sildenafil-d5
Sildenafil-d₅ (UK-92480-d₅) is deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM.

HY-90009AS

Tadalafil-13C2,d3
Tadalafil- ¹³C₂,d₃ is ¹³C and deuterated labeled Tadalafil (HY-90009A). Tadalafil (IC-351) is a *PDE5* inhibitor with an IC₅₀ value of 1.8 nM.

HY-136520S

Xanthoanthrafil-d3
Xanthoanthrafil-d₃ is the deuterium labeled Xanthoanthrafil (HY-136520B). Xanthoanthrafil is a potent phosphodiesterase-5 (PDE5) inhibitor, with an IC₅₀ of 3.95 ng/mL. Xanthoanthrafil can be used for the research of erectile dysfunction .

HY-18253S

Udenafil-d7
Udenafil-d₇ is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research .

HY-B0809S1

Theophylline-d3

Theophylline-d₃ is deuterated labeled Theophylline (HY-B0809). Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-15025S2

Sildenafil-d3-1
Sildenafil-d3-1 (UK-92480-d3-1) is deuterium labeled Sildenafil-d₃. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC₅₀ of 5.22 nM.

HY-B0204S2

Pimobendan-d4
Pimobendan-d₄ (UD-CG115-d₄) is deuterium labeled Pimobendan (HY-B0204). Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM .

HY-167906S

Hexadecyl 2-((4-Nitrophenyl)thio)acetate-13C2
Hexadecyl 2-((4-Nitrophenyl)thio)acetate- ¹³C₂ is the ¹³C-labeled Lunamarine (HY-167906). Lunamarine is a inhibitor of PDE5 with BBB permeability. Lunamarine can be used in the reseach of Pulmonary Arterial Hypertension (PAH) and Erectile Dysfunction (ED) .

HY-W759997

Reproterol-d3
Reproterol-d₃ is the deuterium labeled Reproterol (HY-135490). Reproterol is a dual acting β2-adrenoceptor agonist and PDE inhibitor. The theophylline constituent of Reproterol inhibits phosphodiesterase activity induced by adenylyl cyclase. Reproterol has the potential for asthma research .

HY-108974S

Drotaverine-d10 hydrochloride

Drotaverine-d₁₀ (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects .

HY-90009AS1

Tadalafil-13C2,d3-1
Tadalafil- ¹³C₂,d₃-1 (IC-351- ¹³C₂,d₃-1) is the deuterium and ¹³C-labeled Tadalafil (HY-90009A). Tadalafil (IC-351) is a PDE5 inhibitor with an IC₅₀ value of 1.8 nM.

HY-143683S

Theophylline-13C2,d6

Theophylline- ¹³C₂,d₆ (1,3-Dimethylxanthine- ¹³C₂,d₆) is the deuterium labeled and ¹³C-labeled Theophylline (HY-B0809). Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-B0763S1

Ibudilast-d7

Ibudilast-d₇ is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .

HY-B0763S

Ibudilast-d3

Ibudilast-d₃ (KC-404-d₃) is the deuterium labeled Ibudilast. Ibudilast (KC-404) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .

HY-B0715S3

Pentoxifylline-d3

Pentoxifylline-d₃ (BL-191-d₃) is deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-B0763S2

Ibudilast-d7-1

Ibudilast-d₇-1 is the deuterium labeled Ibudilast . Ibudilast (KC-404;AV-411;MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .

HY-13295S

Vinpocetine-d5

Vinpocetine-d₅ is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC₅₀ value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders .

HY-B0523S

Anagrelide-13C2,15N,d2

Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-W654000

Cyclic GMP-13C,15N2

Cyclic GMP- ¹³C, ¹⁵N₂ is ¹³C and ¹⁵N labeled Cyclic GMP (HY-113469). Cyclic GMP (cGMP), an important second messenger, is a major intracellular mediator of extracellular signals such as nitric oxide (NO) and natriuretic peptides (NPs). Effects of Cyclic GMP occur through three main groups of cellular targets: cGMP-dependent protein kinases (PKGs), cGMP-gated cation channels, and PDEs. Cyclic GMP can inhibit both platelet adhesion and aggregation. cGAMP (Cyclic-GMP-AMP) (HY-12512), a conjugate of Cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses .

HY-17464S3

Cilostazol-d6
Cilostazol-d₆ (OPC 13013-d₆) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of *phosphodiesterase (PDE) 3A, the isoform of PDE* 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-W751650

Sildenafil-d3 citrate
Sildenafil-d₃ citrate (UK-92480-d₃ citrate) is the deuterium labeled Sildenafil citrate (HY-15025A). Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC₅₀ of 5.22 nM.

Host:	Mouse (11) Rabbit (9)
Reactivity:	Human (19) mouse (1) rat (1) Rat (13) Mouse (14) Monkey (2) human (1)
Application:	IHC-P (8) ICC/IF (5) IF-Tissue (1) IP (3) WB (15) FC (10) ELISA (5)
Isotype:	IgG,Kappa (1) IgG (8) IgG1 (6) IgG2a (4) IgG2b (1)
Conjugation:	Non-conjugated (20)
Clonality:	Monoclonal (10) Monoclonal Antibody (2) Recombinant (7)
Modification:	Unmodified (13)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83187

	PDE4B Antibody (YA2932) Dpde4; pde 4B; pde IVB; pde32; pde4b; pde4B5; pdeIVB; Phosphodiesterase 4B	WB, FC	Human, Mouse
	PDE4B Antibody (YA2932) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDE4B.

HY-P83244

	PDE2A Antibody (YA2989) CGS pde; cGSpde; pde2A; pde2A1; pde2A4; phosphodiesterase 2A	WB	Human, Mouse, Rat
	PDE2A Antibody (YA2989) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDE2A.

HY-P88157

	PDE4A Antibody (YA7841) Dpde2; pde4; pde46	WB, IHC-P, ICC/IF, FC	Human, Rat
	PDE4A Antibody (YA7841) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PDE4A.

HY-P88157A

	PDE4A Antibody (YA7841)(PBS only) Dpde2; pde4; pde46	IHC-P, ICC/IF, FC	Human, Rat
	PDE4A Antibody (YA7841) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PDE4A.

HY-P84454

	PDE1B Antibody (YA4151) pde1B1; pdeS1B	WB, IHC-P, FC, ELISA	Human, Rat
	PDE1B Antibody (YA4151) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PDE1B.

HY-P84455

	PDE1B Antibody (YA4152) pde1B1; pdeS1B	WB, FC, ELISA	Human, Mouse, Monkey
	PDE1B Antibody (YA4152) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PDE1B.

HY-P88890

	PDE6G (PDE6 gamma) Antibody (YA8574) pdeG; RP57	FC	Human, Mouse, Rat
	PDE6G (PDE6 gamma) Antibody (YA8574) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PDE6G (PDE6 gamma).

HY-P81969

	PDE4D Antibody (YA1714) cAMP-specific 3' ; 5' -cyclic phosphodiesterase 4D; Dpde3; pde43; pde4D; Dpde3	WB	Human
	PDE4D Antibody (YA1714) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDE4D.

HY-P84454A

	PDE1B Antibody (YA4151)(PBS only) pde1B1; pdeS1B	WB, IHC-P, FC, ELISA	Human, Rat
	PDE1B Antibody (YA4151) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PDE1B.

HY-P84455A

	PDE1B Antibody (YA4152)(PBS only) pde1B1; pdeS1B	WB, FC, ELISA	Human, Mouse, Monkey
	PDE1B Antibody (YA4152) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PDE1B.

HY-P88890A

	PDE6G (PDE6 gamma) Antibody (YA8574)(PBS only) pdeG; RP57	FC	Human, Mouse, Rat
	PDE6G (PDE6 gamma) Antibody (YA8574) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PDE6G (PDE6 gamma).

HY-P81808

	PDE1B Antibody (YA1553) pde1B1; pdeS1B; HEL-S-79p	WB	Human, Mouse, Rat
	PDE1B Antibody (YA1553) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDE1B.

HY-P88414

	PDE1A Antibody (YA8098) CAM-pde-1A; HCAM-1; HCAM1; HSpde1A	IHC-P	Human, Mouse, Rat
	PDE1A Antibody (YA8098) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PDE1A.

HY-P87798

	PDE1B Antibody (YA7483)	WB, IHC-P	Human, Mouse, Rat
	PDE1B Antibody (YA7483) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to PDE1B.

HY-P810276

	PDE3A Antibody (YA9620)	WB, ICC/IF, IF-Tissue, IP, ELISA	human, mouse, rat
	PDE3A Antibody (YA9620) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PDE3A.

HY-P81808A

	PDE1B Antibody (YA1553)(PBS only) pde1B1; pdeS1B; HEL-S-79p	WB	Human, Mouse, Rat
	PDE1B Antibody (YA1553) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDE1B.

HY-P88414A

	PDE1A Antibody (YA8098)(PBS only) CAM-pde-1A; HCAM-1; HCAM1; HSpde1A	IHC-P	Human, Mouse, Rat
	PDE1A Antibody (YA8098) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to PDE1A.

HY-P87358

	PDE10A Antibody (YA7041) 5''-cyclic phosphodiesterase 10A antibody; cAMP and cAMP inhibited cGMP 3'5' cyclic phosphodiesterase 10A antibody; cAMP and cAMP-inhibited cGMP 3'' antibody; FLJ11894 antibody; HSpde 10A antibody; HSpde10A antibody; pde 10A antibody; pde10_HUMAN antibody; pde10a antibody; Phosphodiesterase 10A antibody	WB, IHC-P, FC	Human, Mouse, Rat
	PDE10A Antibody (YA7041) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PDE10A.

HY-P82289

	ALDH7A1 Antibody (YA2034) aldehyde dehydrogenase 7 family member A1; EPD; pde; ATQ1	WB, ICC/IF, IP	Human, Mouse
	ALDH7A1 Antibody (YA2034) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ALDH7A1.

HY-P82289A

	ALDH7A1 Antibody (YA2034)(PBS only) aldehyde dehydrogenase 7 family member A1; EPD; pde; ATQ1	WB, ICC/IF, IP	Human, Mouse
	ALDH7A1 Antibody (YA2034) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ALDH7A1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Targets Recommended: Phosphodiesterase (PDE) Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12318G

IBMX 3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine	Phosphodiesterase (PDE)	Inflammation/Immunology
IBMX (3-Isobutyl-1-methylxanthine) (GMP) is IBMX (HY-12318) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor .

HY-16900G

Rolipram	Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Neurological Disease Inflammation/Immunology Cancer
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a *PDE4* inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

26b pde Inhibitors

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Natural
Products